FTSE 100 today: Index, pound edge higher; StanChart, Revolution Beauty jump
Crispr Therapeutics AG (NASDAQ:CRSP) stock reached a 52-week high, touching 62.32 USD, marking a notable milestone for the biotechnology company. While the stock shows a modest 1-year performance, InvestingPro data reveals impressive gains of nearly 36% over the past six months. The company’s market capitalization now stands at approximately $5 billion, with its stock currently trading above the InvestingPro Fair Value. The company’s stock has been closely watched by investors, given its pioneering role in gene editing technology. The 52-week high underscores investor confidence and interest in Crispr’s potential to drive innovation and growth in the biotech sector. With a strong current ratio of 15.64 and more cash than debt on its balance sheet, the company maintains solid financial flexibility. Discover 12 additional key insights about CRSP with an InvestingPro subscription.
In other recent news, CRISPR Therapeutics has released new data from its Phase 1 CTX310 trial, demonstrating significant reductions in triglycerides and LDL cholesterol, with peak reductions reaching up to 82% and 86%, respectively. Analysts from H.C. Wainwright and Brookline Capital Markets have maintained their Buy ratings, with price targets set at $65.00 and $268.00, respectively, citing the promising results of the trial. Meanwhile, Citizens JMP reiterated a Market Outperform rating, highlighting the potential for CRISPR’s in-vivo gene editing pipeline, despite current market undervaluation. In contrast, Clear Street downgraded its rating from Buy to Hold, expressing concerns over valuation and potential challenges in the commercial launch of Casgevy. Goldman Sachs maintained a Neutral rating, with a $47.00 price target, noting the favorable safety profile of CTX310. Additionally, CRISPR Therapeutics has adjusted its timeline for the CTX320 data release to the first half of 2026, aiming to incorporate insights from the evolving Lp(a) landscape. The company plans to present the full CTX310 data at a medical meeting in the latter half of 2025. These developments reflect ongoing interest and strategic adjustments in CRISPR Therapeutics’ cardiovascular disease programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.